An 83-amino-acid modified version of insulin-like growth factor-1 (IGF-1) with an arginine substitution at position 3 and a 13-amino-acid N-terminal extension. These modifications reduce binding to IGF binding proteins (IGFBPs), resulting in a much longer effective half-life and greater bioavailability than native IGF-1.
IGF-1 LR3 (Long Arg3 Insulin-like Growth Factor-1) is an 83-amino-acid synthetic analog of human IGF-1 (70 amino acids). Two modifications distinguish it from native IGF-1: (1) an arginine replacing glutamic acid at position 3 (Arg3), and (2) a 13-amino-acid N-terminal extension peptide.
These modifications dramatically reduce IGF-1 LR3's binding to the 6 IGF binding proteins (IGFBPs) that normally sequester and inactivate circulating IGF-1. With reduced IGFBP binding, more IGF-1 LR3 remains free and bioactive, extending its effective half-life from ~15 minutes (native IGF-1) to approximately 20-30 hours.
IGF-1 LR3 is the most potent commercially available form of IGF-1. By escaping IGFBP sequestration, it maintains high free IGF-1 levels for 20-30 hours, continuously activating IGF-1R on muscle cells (promoting hypertrophy), fat cells (promoting lipolysis), and satellite cells (promoting regeneration). The mTOR activation is particularly important for muscle protein synthesis — it's the same pathway that leucine and resistance training activate, but IGF-1 LR3 provides sustained stimulation.
| Pathway | Effect | Significance |
|---|---|---|
| Reduced IGFBP binding | Arg3 substitution + N-terminal extension prevent IGFBP sequestration | 3x greater bioactivity than native IGF-1 |
| PI3K-Akt-mTOR | Activates the master anabolic signaling cascade | Increases muscle protein synthesis and inhibits protein degradation |
| Ras-MAPK | Promotes cell proliferation and differentiation | Satellite cell activation for muscle regeneration |
| Anti-apoptotic | Akt phosphorylates Bad, blocking the apoptotic cascade | Promotes cell survival under stress |
| Lipolysis | IGF-1R signaling in adipocytes promotes fat breakdown | Reduces body fat while preserving/building lean mass |
| Study | Design | Findings | Level |
|---|---|---|---|
| Muscle hypertrophy | Preclinical + in vitro | IGF-1 LR3 is ~3x more potent than native IGF-1 in stimulating muscle cell proliferation and differentiation | Preclinical |
| Bioavailability | Pharmacokinetic studies | 20-30 hour effective half-life vs 15 minutes for native IGF-1. Reduced IGFBP binding confirmed. | Level II |
| Wound healing | Preclinical | Accelerated wound closure and tissue remodeling in animal models | Preclinical |
| Mecasermin (native IGF-1) | FDA-approved analog (Increlex) | Native recombinant IGF-1 (not LR3) is FDA-approved for severe IGF-1 deficiency. Provides clinical validation of IGF-1R pathway. | Level I (for native IGF-1) |
Hypoglycemia: IGF-1 can activate insulin receptors at high concentrations. Blood sugar monitoring essential.
Cancer risk: IGF-1 is a potent mitogen. Chronic IGF-1 elevation is associated with increased cancer risk in epidemiological studies.
Organ enlargement: Chronic IGF-1 elevation can cause acromegaly-like effects: enlargement of hands, feet, jaw, and internal organs.
Joint pain: Common at higher doses. Related to tissue growth and fluid retention.
Not well-studied in humans: Most human evidence is from native IGF-1 (mecasermin). IGF-1 LR3 specifically has very limited human safety data.
| Jurisdiction | Status |
|---|---|
| FDA | NOT approved. Native IGF-1 (mecasermin/Increlex) is approved for severe primary IGF-1 deficiency. |
| WADA | Banned under S2 (peptide hormones and growth factors) |
| Availability | Available as a research chemical. Commonly used in bodybuilding communities. |